KYNB Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $6.31
Market Cap (MRQ) $26M
P/E (TTM) 0.1
EPS (TTM) $46.40
Revenue (TTM) $5M
ROE (TTM) -144.7%
52W Range $6–$12

KYNB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 1
Ex-date Split Type
June 17, 2025 1-for-25 Reverse

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$6M
2016-12-31 → 2025-12-31
EPS$45.37
2020-12-31 → 2025-12-31
Free Cash Flow$-5M
2016-12-31 → 2025-12-31
Net margin3967.8%
2016-12-31 → 2025-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend KYNB 5Y avg Peer Median Verdict
P/E (TTM) 0.1 · · ·
P/S (TTM) 5.5 · · ·
P/B (MRQ) -0.8 · · ·
Price / FCF (TTM) -0.7 · · ·
Price / Cash Flow (TTM) -0.7 · · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 52.3%
Next Report Nov 09, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 13, 2026 $-4.69 $-3.25 -44.5%
March 31, 2026 May 11, 2026 $-3.76 $-3.42 -9.9%
Dec. 31, 2025 $-3.61 $-3.96 8.9%
Sept. 30, 2025 $-3.25 $-4.09 20.4%
June 30, 2025 $-1.88 $-2.35 20.0%
March 31, 2025 $1.25 $0.51 145.1%
Dec. 31, 2024 $4.50 $-3.57 226.1%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 16
Metric Trend 202520242023202220212020201920182017201620152014
Revenue $6M$30M$47M$141M$235M$176M$257M$213M$131M$183M$181M$138M
Cost of Revenue $556.0K$16M$4M$20M$13M$9M$1M·····
R&D Expense $24M$96M$266M$297M$387M$253M$209M$236M$197M$187M$214M$151M
SG&A Expense $28M$49M$86M$125M$124M$106M$135M$64M$52M$46M$44M$37M
Operating Expenses $52M$180M$370M$442M$524M$368M$346M$300M$248M$233M$258M$188M
Operating Income $-46M$-150M$-323M$-301M$-289M$-192M$-89M$-87M$-117M$-50M$-78M$-50M
Interest Expense $9M$8M$8M$1M$1M$2M$3M$11M$10M$11M$11M$11M
Other Non-op $3M$5M$8M$8M$-1M$6M$16M·····
Pretax Income $-58M$-153M$-323M$-295M$-291M$-189M$-77M$-86M$-121M$-58M$-86M$-60M
Income Tax $-90.0K$-269.0K$-252.0K$358.0K$347.0K$360.0K$328.0K$304.0K$321.0K$-71.0K$242.0K$0
Net Income $183M$-48M$-284M$-294M$-290M$-189M$-77M$-86M$-121M$-58M$-86M$-60M
EPS (Basic) $45.37$-11.89$-2.92$-3.14$-3.14$-2.11······
EPS (Diluted) $45.37$-11.89$-2.92$-3.14$-3.14$-2.11······
Shares (Basic) 4,043,0004,002,00097,303,00093,582,00092,349,00089,854,000······
Shares (Diluted) 4,043,0004,002,00097,303,00093,582,00092,349,00089,854,000······
EBITDA $-46M$-150M$-282M$-301M$-289M$-192M$-89M$-87M$-123M$-54M$-78M·
Balance Sheet 25
Metric Trend 202520242023202220212020201920182017201620152014
Cash & Equivalents $48M$50M$82M$156M$171M$678M$126M$89M$674M$174M$153M$165M
Short-term Investments $41M$0$122M$266M$234M$8M$407M$532M$62M···
Receivables $216.0K$481.0K$5M$16M$17M$42M$28M$64M$8M$10M$15M$13M
Inventory $4M$3M$17M$40M$31M$17M$7M$0····
Prepaid Expense $6M$32M$40M$14M$20M$10M$133M$5M$5M$3M$4M$5M
Other Current Assets $1M$1M$7M$4M$5M$2M$2M$2M····
Current Assets $99M$197M$332M$493M$474M$755M$702M$690M$749M$267M$201M$198M
PP&E (Net) ·$0$5M$21M$28M$34M$43M$127M$129M$124M$129M$132M
PP&E (Gross) ·$0$118M$149M$149M$145M$143M$192M$189M$177M$177M$174M
Accum. Depreciation ·$0$113M$129M$121M$111M$100M$65M$60M$54M$48M$42M
Other Non-current Assets $361.0K$1M$3M$5M$7M$1M$9M$3M$5M$2M$2M$2M
Total Assets $120M$215M$424M$610M$774M$827M$857M$881M$899M$470M$471M$484M
Accounts Payable $4M$5M$16M$31M$26M$25M$6M$9M$6M$6M$7M$5M
Accrued Liabilities $20M$62M$133M$220M$173M$118M$84M$66M$64M$51M$48M$49M
Current Liabilities $29M$133M$218M$274M$225M$163M$103M$89M$86M$65M$67M$63M
Capital Leases ·$0$65M$80M$89M$853.0K$942.0K$0····
Other Non-current Liabilities $82.0K$822.0K$3M$6M$26M$39M$65M$10M$8M$6M$5M$696.0K
Total Liabilities $115M$398M$586M$612M$545M$385M$322M$352M$351M$294M$274M$243M
Common Stock $1M$1M$988.0K$942.0K$929.0K$914.0K$877.0K$854.0K$825.0K$637.0K$620.0K$590.0K
Paid-in Capital $1.68B$1.67B$1.64B$1.54B$1.48B$1.40B$1.30B$1.23B$1.16B·$587M$546M
Retained Earnings $-1.71B$-1.89B$-1.84B$-1.56B$-1.26B$-974M$-785M$-716M$-631M$-510M$-452M$-322M
AOCI $-2M$-6M$-7M$-6M$-4M$-4M$-747.0K$-2M$-2M$-960.0K$-2M$-3M
Stockholders' Equity $-30M$-226M$-204M$-21M$209M$422M$516M$509M$528M$156M$178M$221M
Liabilities + Equity $120M$215M$424M$610M$774M$827M$857M$881M$899M$470M$471M$484M
Shares Outstanding 4,047,0004,037,00098,770,00094,166,00092,881,00091,441,00087,657,00085,432,00082,498,00063,665,00061,985,00059,046,000
Cash Flow 13
Metric Trend 202520242023202220212020201920182017201620152014
Stock-based Comp $7M$25M$51M$66M$71M$73M$66M$52M$38M$32M$28M$19M
Deferred Tax $0$0$0$0$0$0$0$0$0$-212.0K$0$0
Restructuring $553.0K$19M$13M$0$0·······
Operating Cash Flow $-5M$-138M$-315M$-146M$-82M$82M$-79M$-76M$-67M$7M$-19M$22M
CapEx $38.0K$266.0K$3M$4M$5M$4M$6M$8M$8M$1M$2M$8M
Investing Cash Flow $35M$126M$154M$89M$-427M$452M$120M$-522M$70M$7M··
Stock Issued $0$139.0K$4M$4M$13M$38M$21M$30M$35M$10M$15M$2M
Net Stock Activity $0$139.0K$4M$4M$13M$38M$21M$30M$35M$10M$13M·
Financing Cash Flow $-86M$-255.0K$123M$47M$-563.0K$13M$-4M$14M$496M$7M··
Net Change in Cash $-54M$-12M$-42M$-16M$-507M$552M$37M$-584M$500M$20M$-12M$89M
Taxes Paid $0$0··········
Free Cash Flow $-5M$-138M$-318M$-150M$-87M$78M$-84M$-84M$-75M$6M$-21M·
Levered FCF $-14M$-146M$-333M$-151M$-88M$75M$-87M$-95M$-85M$-5M$-32M·
Profitability 7
Metric Trend 202520242023202220212020201920182017201620152014
Operating Margin -712.7%-507.8%-190.7%-213.9%-122.6%-108.8%-34.8%-40.7%-97.6%-29.9%-42.9%·
Net Margin 2848.6%-160.6%-192.4%-208.7%-123.2%-107.4%-30.0%-40.6%-100.4%-34.4%-47.4%·
Pretax Margin -905.2%-517.8%-194.2%-209.5%-123.5%-107.1%-29.9%-40.4%-100.2%-34.4%-47.3%·
EBITDA Margin -712.7%-507.8%-190.7%-213.9%-122.6%-108.8%-34.8%-40.7%-97.6%-29.9%-42.9%·
ROA 109.8%-14.9%-55.0%-42.4%-36.2%-22.5%-8.9%-9.7%-18.4%-13.1%-18.0%·
ROE -143.5%22.1%252.0%-312.9%-91.9%-40.4%-15.0%-16.7%-35.1%-37.0%-43.0%·
ROIC 152.6%66.6%138.0%1405.3%-138.1%-45.5%-17.4%-17.1%-21.8%-34.4%-43.8%·
Liquidity & Solvency 3
Metric Trend 202520242023202220212020201920182017201620152014
Current Ratio 3.41.51.51.82.14.66.87.89.74.13.0·
Quick Ratio 3.10.41.11.61.94.55.57.78.82.82.5·
Interest Coverage -5.2-18.2-18.1-209.0-268.4-79.9-31.1-7.9-12.6-5.0-7.0·
Efficiency 3
Metric Trend 202520242023202220212020201920182017201620152014
Asset Turnover 0.00.10.30.20.30.20.30.20.20.40.4·
Inventory Turnover 0.21.50.50.60.5·······
Receivables Turnover 18.510.610.28.47.95.05.65.913.313.912.5·
Per Share 5
Metric Trend 202520242023202220212020201920182017201620152014
Book Value / Share $-7.42$-2.24$-2.07$-0.23$2.25$4.62$5.89$5.96$6.83$2.45$2.86·
Revenue / Share $1.59$0.30$1.52$1.50········
Cash Flow / Share $-1.18$-1.38$-3.24$-1.56········
Cash / Share $11.83$0.50$1.15$1.65$1.84$7.42$1.44$1.04$8.17$2.73$2.47·
EPS (TTM) $45.37$-11.89$-2.92$-3.14$-3.14$-2.11······
Growth Rates 3
Metric Trend 202520242023202220212020201920182017201620152014
Revenue YoY -78.3%-36.7%-66.7%-40.2%33.5%·······
Revenue CAGR 3Y -64.2%-49.9%-35.7%·········
Revenue CAGR 5Y -48.4%···········
Valuation (TTM) 9
Metric Trend 202520242023202220212020201920182017201620152014
Revenue TTM $6M$30M$47M$141M$235M$176M$257M$213M$131M$183M$181M$138M
Net Income TTM $183M$-48M$-284M$-294M$-290M$-189M$-77M$-86M$-121M$-58M$-86M$-60M
Market Cap $36M$1.34B··········
P/E 0.2-1.1··········
P/S 5.545.1··········
P/B -1.2-5.9··········
P / Cash Flow -7.4-9.7··········
P / FCF -7.4-9.7··········
Earnings Yield 516.7%-89.7%··········

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $6M $30M $47M $141M $235M
Operating Margin % -712.7% -507.8% -190.7% -213.9% -122.6%
Net Income $183M $-48M $-284M $-294M $-290M
Diluted EPS $45.37 $-11.89 $-2.92 $-3.14 $-3.14

Institutional owners (13F) 33 filers · $9.2M total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 33
Value held $9.2M
New positions 1
Exited positions 5
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
1 (-7 vs prior Q) 5 (-1 vs prior Q) 6 (+1 vs prior Q) 8 (-1 vs prior Q) -36K

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
ARMISTICE CAPITAL, LLC $3,020,000 400,000 32.66% Shares
VANGUARD GROUP INC $1,597,723 181,973 17.28% Shares
VANGUARD CAPITAL MANAGEMENT LLC $1,207,623 159,950 13.06% Shares
SUSQUEHANNA INTERNATIONAL GROUP, LLP $674,970 89,400 7.30% Call option
BlackRock, Inc. $636,692 84,330 6.89% Shares
GEODE CAPITAL MANAGEMENT, LLC $326,385 43,219 3.53% Shares
HighTower Advisors, LLC $300,082 39,746 3.25% Shares
TWO SIGMA INVESTMENTS, LP $298,308 39,511 3.23% Shares
RENAISSANCE TECHNOLOGIES LLC $204,462 27,081 2.21% Shares
TWO SIGMA ADVISERS, LP $200,263 22,809 2.17% Shares
VANGUARD FIDUCIARY TRUST CO $181,993 24,105 1.97% Shares
Birchview Capital, LP $170,373 22,566 1.84% Shares
STATE STREET CORP $153,144 20,284 1.66% Shares
WOLVERINE TRADING, LLC $142,854 11,600 1.54% Call option
UBS Group AG $59,320 7,857 0.64% Shares
GROUP ONE TRADING LLC $33,265 4,406 0.36% Shares
Vanguard Global Advisers, LLC $10,751 1,424 0.12% Shares
Tower Research Capital LLC (TRC) $8,403 1,113 0.09% Shares
Axiom Investment Management LLC $5,315 704 0.06% Shares
MORGAN STANLEY $3,677 487 0.04% Shares
CIBC Private Wealth Group LLC $3,516 287 0.04% Shares
HARBOUR INVESTMENTS, INC. $1,510 200 0.02% Shares
NATIONAL BANK OF CANADA /FI/ $1,448 193 0.02% Shares
OSAIC HOLDINGS, INC. $1,374 182 0.01% Shares
SBI Securities Co., Ltd. $1,148 152 0.01% Shares
ROYAL BANK OF CANADA $1,000 138 0.01% Shares
ACADIAN ASSET MANAGEMENT LLC $795 105,585 0.01% Shares
BNP PARIBAS FINANCIAL MARKETS $347 46 0.00% Shares
CWM, LLC $176 26 0.00% Shares
GSA CAPITAL PARTNERS LLP $119 15,697 0.00% Shares
JPMORGAN CHASE & CO $88 12 0.00% Shares
DANSKE BANK A/S $8 1 0.00% Shares
Smithfield Trust Co $0 1 0.00% Shares

Company insiders 30 insiders · 12 officers · 20 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Thane Wettig CEO Sept. 6, 2026 F 26,796 4 0 $73,454
Enrique A Conterno Chief Executive Officer July 7, 2023 S 374,722 0 0 $0
Thomas B Neff Chief Executive Officer Aug. 22, 2019 M 44,238 0 0 $0
David Delucia Chief Financial Officer Sept. 6, 2026 F 4,355 0 0 $0
Juan Graham CHIEF FINANCIAL OFFICER Dec. 7, 2024 F 164,863 0 0 $0
Pat Controneo Executive Advisor & Former CFO Sept. 7, 2021 F 274,536 0 0 $0
Christine Chung SVP, CHINA OPERATIONS March 6, 2025 F 294,903 0 0 $0
Deyaa Adib Chief Medical Officer June 12, 2024 P 82,123 0 0 $0
Mark Eisner EVP, Chief Medical Officer Sept. 6, 2023 F 159,917 0 0 $0
Elias Kouchakji SVP, Clinical Dev, Drug Safety March 8, 2021 F 147,346 0 0 $0
Peony K Yu Chief Medical Officer Dec. 16, 2020 S 192,292 0 0 $0
Frank H Valone MD Chief Medical Officer April 1, 2016 M 104,684 0 0 $0
Maykin Ho Director June 12, 2026 A 31,501 0 0 $0
James A Schoeneck Director June 12, 2026 A 39,666 0 0 $0
Michael Kauffman Director June 12, 2026 A · 0 0 $0
Jeffrey L Edwards Director June 12, 2026 A 33,977 0 0 $0
Benjamin Cravatt Director June 5, 2024 A 28,736 0 0 $0
Suzanne Blaug Director June 5, 2024 A 29,594 0 0 $0
Gerald Lema Director June 5, 2024 A 28,766 0 0 $0
Aoife Brennan Director June 5, 2024 A 27,947 0 0 $0
Jeffrey William Henderson Director Sept. 1, 2023 S 28,866 0 0 $0
Thomas F Kearns JR Director Sept. 15, 2021 S 39,764 0 0 $0
Kalevi Kurkijarvi Director May 26, 2021 A 37,800 0 0 $0
Rory B Riggs Director May 26, 2021 A 395,750 0 0 $0
Roberto Pedro Rosenkranz Director June 9, 2020 M 96,100 0 0 $0
Toshinari Tamura Director June 5, 2019 A 56,400 0 0 $0
Jorma Routti Director March 26, 2019 M 161,540 0 0 $0
Julian N Stern Director June 8, 2016 A 161,068 0 0 $0
Miguel Madero Director Dec. 8, 2015 M 55,614 0 0 $0
Astellas Pharma Inc. · Nov. 19, 2014 C 4,968,367 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 2 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
VXF · VANGUARD INDEX FUNDS 0.00% 42,265 SH Aug. 19, 2026 Daily
VTI · VANGUARD INDEX FUNDS 0.00% 114,179 SH Aug. 19, 2026 Daily

KYNB Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 9 analysts BUY
Median target $41.00 +549.8%
3 33.3% Strong Buy
4 44.4% Buy
2 22.2% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

3 analysts · 2026-10-02

Mean target $39.67 +528.6%

← Below all targets Current price $6.31
Low$35.00 Mean$39.67 High$43.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
KYNB $36M 0.2 -78.3% 2848.6% -143.5% ·
ATYR $77M -1.0 -19.1% -39009.5% -107.8% ·
RNAZ · -0.1 · · · ·
SHPH $4M -0.3 0.00% · -400.1% ·
GRDX $20M -1.1 · -17634.4% -68.6% -1813.6%
ATOS $5M -0.1 · · -71.7% ·
NXTC $50M -0.7 · · -172.9% ·
TCRX · -1.0 266.7% -1256.8% -86.6% ·

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 13, 2026